|Over a week ago|
iBio says immunization studies for SARS-CoV-2 VLP program are proceeding » 07:3703/2603/26/20
iBio announced that…
iBio announced that immunization studies for its SARS-CoV-2 Virus-Like Particle program are proceeding at Texas A&M University System laboratories. The work is being performed as part of the Master Joint Development Agreement established between iBio and TAMUS in 2016. iBio created its proprietary VLP candidates in just a few weeks using its FastPharming System. iBio's researchers then deployed this plant-based expression platform's rapid production capabilities to deliver VLPs suitable for further development just weeks after the biologics were designed.
Nearly 70 drugs may be effective in treating coronavirus, NY Times reports » 06:1403/2303/23/20
INO, CODX, IBIO, NNVC
Scientists have identified nearly 70 drugs to test against the coronavirus, The New York Times' Carl Zimmer reports. According to a team of researchers, some of the medications are already used to treat other diseases, and repurposing them to treat Covid-19, the illness caused by the coronavirus, may be faster than trying to invent a new antiviral from scratch. On the list are haloperidol, used to treat schizophrenia, and metformin, taken by people with Type 2 diabetes, as well as antibiotics that kill bacteria by gumming up the cellular machinery they use to build proteins, and chloroquine. Small-to-mid cap publicly traded companies working on coronavirus treatment and testing include Inovio (INO), Co-Diagnostics (CODX), iBio (IBIO) and NanoViricides (NNVC). Reference Link
iBio joins Alliance for Biosecurity » 07:3403/2003/20/20
iBio announced that it…
iBio announced that it has joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies - along with laboratory and academic partners - that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available. The Alliance for Biosecurity supports national health security by advocating for public policies and funding to support the rapid development, production, stockpiling, and distribution of critically needed medical countermeasures that are used to prevent and respond to a variety of threats.
White House sought to exand virus drug tests over objections from FDA, WSJ says » 11:3803/1803/18/20
INO, CODX, IBIO, NNVC
The White House…
The White House considered issuing an executive order to significantly expand the use of investigational drugs against the new coronavirus, but the FDA's senior scientists warned it could pose unneeded risks to patients, The Wall Street Journal's Thomas M. Burton reports, citing a senior government official. President Trump tweeted that he is planning a briefing Wednesday that will pertain to the FDA, but it is unclear if that briefing would deal with expanded use of testing drugs against the virus. Small-to-mid cap publicly traded companies working on coronavirus treatment and testing include Inovio (INO), Co-Diagnostics (CODX), iBio (IBIO) and NanoViricides (NNVC). Reference Link
iBio announces development of COVID-19 vaccine candidates » 08:0503/1803/18/20
iBio announced its…
iBio announced its progress towards developing vaccine candidates for preventing infection from the SARS-CoV-2 virus that causes the COVID-19 coronavirus disease. iBio created its SARS-CoV-2 Virus-Like Particle-based constructs in just a few weeks using its FastPharming System to produce the nanoparticles in, and purify them from, plants. The manufacturing platform not only provides for rapid development of research quantities of product, but also high-quality material that is readily scalable for producing doses for clinical trials and commercial use. On March 11, 2020, iBio filed four provisional patent applications with the U.S. Patent and Trademark Office in support of the VLP platform, as well as other technologies for treating or preventing infections with the SARS-CoV-2 virus.
FDA to let private companies market COVID-19 tests without approval, WSJ says » 06:1003/1703/17/20
INO, CODX, IBIO, NNVC
The FDA will allow…
The FDA will allow private companies to begin marketing coronavirus test kits directly to the public, in a move to ease a shortage of test kits, The Wall Street Journal's Thomas M. Burton reports. The FDA will review the accuracy of test data submitted by the manufacturers retroactively, which FDA Commissioner Stephen Hahn says has risks, but is warranted by the severity of the pandemic. Small-to-mid cap publicly traded companies working on coronavirus treatment and testing include Inovio (INO), Co-Diagnostics (CODX), iBio (IBIO) and NanoViricides (NNVC). Reference Link
iBio names Thomas Isett co-chairman, CEO » 16:4503/1203/12/20
iBio announced the…
iBio announced the appointment of accomplished life sciences executive, Thomas F. Isett, as its Co-Chairman and Chief Executive Officer. Mr. Isett, a current member of iBio's Board of Directors, succeeds Robert B. Kay, who has retired from the role as Chief Executive Officer, but will remain as Co-Chairman and member of the Board. "I believe Tom is exceptionally well-qualified to lead iBio as we continue to pursue additional commercial applications of our FastPharming System, expand our CDMO business and advance our proprietary product pipeline," said Mr. Kay. "In the time that we have worked together on the Board, Tom has earned my deep personal admiration and great professional respect, and while it has been a pleasure leading iBio to this stage, I am confident that I am passing the torch into the right hands."
House democrats expected to unveil coronavirus package Wednesday, The Hill says » 11:2903/1103/11/20
INO, CODX, IBIO, NNVC
House Democrats are…
House Democrats are expected to unveil a package Wednesday afternoon ahead of a planned vote this week to help boost the economy hit by the coronavirus outbreak, The Hill's Cristina Marcos writes. Bipartisan discussions are still ongoing between Speaker Nancy Pelosi and Treasury Secretary Steven Mnuchin, but Democrats are still planning to move their own proposals to help mitigate the economic effects of the coronavirus, the author adds. House Democrats are expected to meet at 4 p.m. to discuss the package, with a floor vote as soon as Thursday. Small-to-mid cap publicly traded companies working on coronavirus treatment and testing include Inovio (INO), Co-Diagnostics (CODX), iBio (IBIO), and NanoViricides (NNVC). Reference Link
Inovio slides after Citron short report calls for SEC investigation » 14:3103/0903/09/20
INO, TWST, CODX, IBIO, NNVC
Shares of Inovio…
Citron Research says SEC should halt Inovio, sees stock trading back to $2 » 11:0403/0903/09/20
INO, CODX, IBIO, APT, AHPI, LAKE, NNVC
Andrew Left's Citron…
Andrew Left's Citron Research said via Twitter that it believes the U.S. Securities and Exchange Commission should "immediately" halt Inovio (INO) and investigate the company's 3-hour vaccine development claim. SEC 'SHOULD HALT' INOVIO: Via Twitter, Citron Research said that "$INO. SEC should immediately HALT this stock and investigate the ludicrous and dangerous claim that they designed a vaccine in 3 hours. This has been a serial stock promotion for years. This will trade back to $2. Investors have been warned." COVID-19 OUTBREAK: Several research groups and pharmaceutical companies around the world are said to be working on a vaccine as COVID-19 continues to spread. On March 4, Stifel analyst Stephen Willey noted that following the White House Coronavirus Task Force meeting in Washington D.C., there was an announcement of the acceleration of development timelines for Inovio's COVID-19 DNA vaccine candidate INO-4800, with human trials now set to begin next month. This morning, Inovio announced that it entered into a second amendment to the At-the-Market equity offering sales agreement dated May 25, 2018 with Stifel for $50M in common stock. Other small-to-mid cap publicly traded companies working on coronavirus treatment and testing include Co-Diagnostics (CODX), iBio (IBIO), and NanoViricides (NNVC). PRICE ACTION: In morning trading, shares of Inovio have fallen about 6.5% to $13.17. The stock was halted earlier on Monday due to volatility.